Earnings Releases·Nov 12, 2026, 7:33 AM ET

Altimmune — Third Quarter 2026 Earnings Summary

Net loss widened to $31.6 million ($0.15/share) for Q3 2026 from $19.0 million ($0.21/share) in the prior year period, driven by R&D expenses rising to $27.0 million from $15.0 million; revenue remained negligible at $0.
Pemvidutide secured FDA Breakthrough Therapy Designation for MASH and Fast Track designation for AUD, while the global PERFORMA Phase 3 trial in MASH targets topline data in 2029 and an FDA End-of-Phase 2 meeting for the AUD program is scheduled for December 2026.
Cash and investments totaled $480 million as of September 30, 2026, with total assets increasing to $495.6 million from $279.9 million at year-end 2025, while the weighted-average shares outstanding rose to 205.3 million from 89.4 million in the prior year.
The company appointed two new directors in October 2026 and relocated its corporate headquarters to Morristown, New Jersey in November 2026, maintaining a strategy to build a liver franchise around pemvidutide.